Krystal Biotech Inc
NASDAQ:KRYS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Krystal Biotech Inc
NASDAQ:KRYS
|
US |
|
K
|
Krystal Biotech Inc
F:4KB
|
US |
Intrinsic Value
The intrinsic value of Krystal Biotech Inc (KRYS) under the Base Case is 251.53 USD per share.
Compared with the current market price of 302.03 USD, the stock appears
Overvalued by 17% .
The intrinsic value is calculated using valuation multiples.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Krystal Biotech Does
Krystal Biotech is a biotechnology company that develops gene therapies for rare diseases, especially inherited skin disorders. Its main product is a topical gene therapy designed to help patients with dystrophic epidermolysis bullosa, a serious condition that makes the skin extremely fragile. The company also works on additional gene therapy programs that use the same core technology.
- Headquarters
- United States of America US
- Employees
- 295
- IPO date
- Sep 20, 2017
Krystal Biotech has a wide economic moat
Patents and regulatory approvals protect Krystal’s specific gene therapy from direct copying, while its ready-made topical treatment avoids the patient-specific cell production and surgical application required by Abeona’s Zevaskyn for recessive DEB. Together, these barriers make Krystal’s treatment harder to reproduce and less resource-intensive to deliver than that rival’s approach.
Read the full moat analysis
Revenue & Expenses Breakdown
Krystal Biotech Inc
Earnings Waterfall
Krystal Biotech Inc
The intrinsic value for Krystal Biotech Inc (KRYS) under the Base Case is 251.53 USD.
Compared with the current market price of 302.03 USD, the stock appears Overvalued by 17% .
